RSV Immunisations 2024

A Prior Information Notice
by SECRETARY OF STATE FOR HEALTH AND SOCIAL CARE ACTING AS PART OF THE CROWN THROUGH UK HEALTH SECURITY AGENCY

Source
Find a Tender
Type
Future Contract (Supply)
Duration
not specified
Value
___
Sector
HEALTH
Published
27 Nov 2023
Delivery
not specified
Deadline
n/a

Concepts

Location

London

Geochart for 1 buyers and 0 suppliers

1 buyer

Description

The provision of immunisation products indicated for the prevention or protection from Respiratory Syncytial Virus (RSV) lower respiratory tract disease

Lot Division

1 A monoclonal antibody for infants

The provision of a product indicated for the prevention or protection from Respiratory Syncytial Virus (RSV) in infants from birth, including pre-term infants, weighing less than 5 kilograms by direct passive immunisation of the infant by means of a monoclonal antibody. The contracting authority estimates their requirement for deliveries between 1 July 2024 and 30 June 2026 ('Initial Term') of the contract to be up to 1.6 million doses, with the option to extend for up to an additional 24 months.
2 A vaccine which provides maternal protection

The provision of a product indicated for the prevention or protection from RSV in infants by means of a vaccination given to pregnant women. The contracting authority estimates their requirement for deliveries between 1 July 2024 and 30 June 2026 ('Initial Term') of the contract to be up to 1.69 million doses, with the option to extend for up to an additional 24 months.
3 A vaccine for older adults (annual cohort)

The provision of a product indicated for the prevention or protection from Respiratory Syncytial Virus (RSV) in a routine single annual cohort of older adults. The contracting authority estimates their requirement for deliveries between 1 July 2024 and 30 June 2026 ('Initial Term') of the contract to be up to 1.45 million doses, with the option to extend for up to an additional 24 months.
4 A vaccine for older adults (annual cohort and a catch-up volume)

The provision of a product indicated for the prevention or protection from Respiratory Syncytial Virus (RSV) in a routine single annual cohort of older adults with a catch up for multiple cohorts in the first year. The contracting authority estimates their requirement for deliveries between 1 July 2024 and 30 June 2026 ('Initial Term') of the contract to be up to 4 million doses, with the option to extend for up to an additional 24 months.

CPV Codes

  • 33651600 - Vaccines
  • 33651500 - Immune sera and immunoglobulins

Indicators

Reference

Domains